AstraZeneca seeks more US approvals for Seroquel XR

LONDON, Feb 29 (Reuters) - AstraZeneca (AZN.L) said on Friday it had submitted a once-daily version of its blockbuster Seroquel medicine for approval by U.S. regulators to treat severe depression in adults.

The Anglo-Swedish drugmaker said it was seeking approval for Seroquel XR to treat major depressive disorder on its own, alongside other treatments and as a maintenance therapy. (Reporting by Mark Potter; Editing by Erica Billingham)